Long Non-Coding RNAs (lncRNAs) in Cardiovascular Disease Complication of Type 2 Diabetes

The discovery of non-coding RNAs (ncRNAs) has opened a new paradigm to use ncRNAs as biomarkers to detect disease progression. Long non-coding RNAs (lncRNA) have garnered the most attention due to their specific cell-origin and their existence in biological fluids. Type 2 diabetes patients will develop cardiovascular disease (CVD) complications, and CVD remains the top risk factor for mortality. Understanding the lncRNA roles in T2D and CVD conditions will allow the future use of lncRNAs to detect CVD complications before the symptoms appear. This review aimed to discuss the roles of lncRNAs in T2D and CVD conditions and their diagnostic potential as molecular biomarkers for CVD complications in T2D.

Automated summary

The discovery of non-coding RNAs as potential biomarkers for disease progression, particularly in type 2 diabetes (T2D) and cardiovascular disease (CVD), highlights the importance of understanding the roles of long non-coding RNAs (lncRNAs) in these conditions. Utilizing lncRNAs as early diagnostic molecular biomarkers for CVD complications in T2D patients shows promise for future clinical applications.